Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allovir Inc
(NQ:
ALVR
)
0.7745
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allovir Inc
< Previous
1
2
3
4
5
Next >
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
February 15, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
February 01, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
January 09, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
December 10, 2022
From
AlloVir
Via
Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 15, 2022
From
AlloVir
Via
Business Wire
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Third Quarter 2022 Financial Results
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Second Quarter 2022 Financial Results
August 04, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces $126.6 Million Registered Direct Offering
July 27, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
June 07, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports First Quarter 2022 Financial Results
May 05, 2022
From
AlloVir, Inc.
Via
Business Wire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
April 20, 2022
From
AlloVir
Via
Business Wire
AlloVir Appoints Shawn Tomasello to Its Board of Directors
March 31, 2022
From
AlloVir
Via
Business Wire
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
March 22, 2022
From
AlloVir
Via
Business Wire
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022
From
AlloVir
Via
Business Wire
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
February 10, 2022
From
AlloVir
Via
Business Wire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
January 05, 2022
From
AlloVir
Via
Business Wire
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
AlloVir
Via
Business Wire
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
December 16, 2021
From
AlloVir
Via
Business Wire
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
December 11, 2021
From
AlloVir
Via
Business Wire
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Third Quarter 2021 Financial Results
November 05, 2021
From
AlloVir
Via
Business Wire
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
October 04, 2021
From
AlloVir, Inc.
Via
Business Wire
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
September 29, 2021
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Second Quarter 2021 Financial Results
August 06, 2021
From
AlloVir
Via
Business Wire
AlloVir Reports First Quarter 2021 Financial Results
May 06, 2021
From
AlloVir
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.